Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Middleton

Showing results (391-400 of 522) with videos related to

Pageof 53
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumorsV M Macaulay, M R Middleton, A S Protheroe, et al.
Cancer Chemotherapy and Pharmacology|February 21, 2013
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiationRuth Plummer, Paul Lorigan, Neil Steven, et al.
The British Journal of Dermatology|July 17, 2013
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY studyP Lorigan, M Marples, M Harries, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|October 6, 2017
Pseudocyclic Arylbenziodoxaboroles: Efficient Benzyne Precursors Triggered by Water at Room TemperatureAkira Yoshimura, Jonathan M Fuchs, Kyle R Middleton, et al.
Radiology Case Reports|September 28, 2018
Long-term radiological and histological outcomes following selective internal radiation therapy to liver metastases from breast cancerPaul C Lyon, Helen Winter, Karin Herbschleb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatribAmanda J Watson, Ami Sabharwal, Mary Thorncroft, et al.
British Journal of Cancer|May 19, 2011
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancerO A Khan, A D Blann, M J Payne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid TumorsValentine M Macaulay, Mark R Middleton, S Gail Eckhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2003
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanomaB W Hancock, K Wheatley, S Harris, et al.
Frontiers in Oncology|May 21, 2016
Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFRTamara Aleksic, Lisa Browning, Martha Woodward, et al.
Pageof 53

Showing results (391-400 of 522) with videos related to

Sort By:
Pageof 53
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumorsV M Macaulay, M R Middleton, A S Protheroe, et al.
Cancer Chemotherapy and Pharmacology|February 21, 2013
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiationRuth Plummer, Paul Lorigan, Neil Steven, et al.
The British Journal of Dermatology|July 17, 2013
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY studyP Lorigan, M Marples, M Harries, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|October 6, 2017
Pseudocyclic Arylbenziodoxaboroles: Efficient Benzyne Precursors Triggered by Water at Room TemperatureAkira Yoshimura, Jonathan M Fuchs, Kyle R Middleton, et al.
Radiology Case Reports|September 28, 2018
Long-term radiological and histological outcomes following selective internal radiation therapy to liver metastases from breast cancerPaul C Lyon, Helen Winter, Karin Herbschleb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatribAmanda J Watson, Ami Sabharwal, Mary Thorncroft, et al.
British Journal of Cancer|May 19, 2011
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancerO A Khan, A D Blann, M J Payne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2016
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid TumorsValentine M Macaulay, Mark R Middleton, S Gail Eckhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2003
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanomaB W Hancock, K Wheatley, S Harris, et al.
Frontiers in Oncology|May 21, 2016
Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFRTamara Aleksic, Lisa Browning, Martha Woodward, et al.
Pageof 53